These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33519940)

  • 1. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review.
    Kassianides X; Bhandari S
    Drugs Context; 2021; 10():. PubMed ID: 33519940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe Symptomatic Hypophosphataemia as a Complication of Parenteral Iron Replacement.
    Teh KK; Chuah MB; Tay SW; Lim AY; Khoo JJ
    Eur J Case Rep Intern Med; 2020; 7(11):001860. PubMed ID: 33194864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe hypophosphataemia following ferric carboxymaltose infusion in paediatric patients with inflammatory bowel disease.
    Harris RE; Armstrong L; Curtis L; Garrick V; Gervais L; Tayler R; Hansen R; Russell RK
    Frontline Gastroenterol; 2020; 11(4):324-326. PubMed ID: 32587674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferric carboxymaltose: a review of its use in iron deficiency.
    Keating GM
    Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction.
    Ifie E; Oyibo SO; Joshi H; Akintade O
    Endocrinol Diabetes Metab Case Rep; 2019 Aug; 2019(1):. PubMed ID: 31385673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric carboxymaltose (Ferinject®) associated hypophosphataemia: case report illustrating the need for increased awareness to minimise incidence and risk.
    Fisher S; Jonker L
    Acute Med; 2020; 19(2):102-105. PubMed ID: 32840261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe hypophosphataemia after intravenous iron administration.
    Blazevic A; Hunze J; Boots JM
    Neth J Med; 2014 Jan; 72(1):49-53. PubMed ID: 24457442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypophosphataemia after intravenous iron administration.
    Anand G; Schmid C
    BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28289000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
    Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
    J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial.
    Vanobberghen F; Lweno O; Kuemmerle A; Mwebi KD; Asilia P; Issa A; Simon B; Mswata S; Schmidlin S; Glass TR; Abdulla S; Daubenberger C; Tanner M; Meyer-Monard S
    Lancet Glob Health; 2021 Feb; 9(2):e189-e198. PubMed ID: 33245866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: a narrative review.
    Daniilidis A; Panteleris N; Vlachaki E; Breymann C; Assimakopoulos E
    J Obstet Gynaecol; 2018 May; 38(4):443-447. PubMed ID: 29057687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
    Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
    Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY
    Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose.
    Rosano G; Schiefke I; Göhring UM; Fabien V; Bonassi S; Stein J
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33172157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aksan A; Işık H; Radeke HH; Dignass A; Stein J
    Aliment Pharmacol Ther; 2017 May; 45(10):1303-1318. PubMed ID: 28326596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.